Browsing Category
Pharma Industry News
4745 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Mirion Medical showcases advanced radiopharma safety and dosimetry systems at SNMMI 2025 in New Orleans
Mirion Medical unveils new radiation safety and workflow tools for radiopharma and theranostics at SNMMI 2025. Explore their latest innovations.
PharmaJet and Immuno Cure partner to launch needle-free HIV therapeutic DNA vaccine trial using Tropis intradermal device
PharmaJet and Immuno Cure sign agreement to use the Tropis intradermal system in a needle-free human trial for a promising HIV DNA vaccine candidate.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Dr. Reddy’s company profile: Respiratory, generics, and global drug pipeline in 2025
Explore Dr. Reddy’s FY25 financials, drug pipeline, and global expansion strategy—see why it’s gaining attention in pharma investment circles.
What is HARLIKU and how will Cycle’s FDA-approved AKU drug help patients starting July 2025?
Cycle Pharmaceuticals secures FDA approval for HARLIKU™, the first approved treatment for alkaptonuria (AKU); launch in the U.S. expected July 2025.
Dr. Takuma Hayashi identifies LMP2 deficiency as key to uterine LMS, ushering in new era of precision cancer treatment
Dr. Takuma Hayashi’s molecular discovery of LMP2 deficiency in uterine LMS marks a breakthrough in precision oncology, unlocking new diagnostic and treatment pathways.
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.
How are AI models and new clinical treatments reshaping diabetes care after the 2025 ADA conference?
ADA 2025 highlights AI diagnostics and breakthrough injectables in diabetes care, signaling early detection and superior glycemic control in clinical trials.
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.
MetaVia unveils synergistic liver disease data on DA-1241 and Efruxifermin at ADA 2025
MetaVia unveils ADA 2025 pre-clinical data showing DA-1241 and Efruxifermin combo improves MASH liver inflammation and fibrosis beyond monotherapies.